Global Continuous Glucose Monitoring Devices Market Is Estimated To...

Global Continuous Glucose Monitoring Devices Market Is Estimated To Witness High Growth Owing To Technological Advancements and Increasing Prevalence of Diabetes

Сообщение 2023-10-03 13:19:55

2Кб

The Global Continuous Glucose Monitoring Devices Market is estimated to be valued at US$ 5.89 Bn in 2022 and is expected to exhibit a CAGR of 9.9% over the forecast period of 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Continuous glucose monitoring devices are used for real-time monitoring of blood glucose levels in individuals with diabetes. These devices provide accurate, frequent, and continuous glucose measurements, allowing patients to make informed decisions about their insulin dosage and overall diabetes management. The market offers various products such as wearable sensors, transmitters, receivers, and insulin pumps, which are widely adopted in hospitals, clinics, and homecare settings. With the advancement in technology, continuous glucose monitoring devices have become smaller, more accurate, and less invasive, leading to increased patient convenience and improved diabetes management.

Market Dynamics:
The growth of the continuous glucose monitoring devices market is primarily driven by the technological advancements in wearable device technology, which have led to the development of smaller and more accurate devices. These devices offer real-time data and alerts for better diabetes management. Additionally, the increasing prevalence of diabetes worldwide is further propelling the demand for continuous glucose monitoring devices. According to the International Diabetes Federation, the global prevalence of diabetes is expected to reach 700 million by 2045. This, coupled with the rising awareness about diabetes management and the need for continuous monitoring, is expected to drive the market growth.

SWOT Analysis:

Strengths:
- Continuous Glucose Monitoring Devices (CGMD) have become an essential tool for managing diabetes, as they provide real-time monitoring and help in making informed decisions regarding insulin dosing and lifestyle adjustments.
- The CGMD market is witnessing continuous technological advancements, such as the integration of artificial intelligence and machine learning, which enhance device accuracy and usability.
- The increasing prevalence of diabetes and the rising awareness about the benefits of CGMD among patients and healthcare professionals are driving the growth of the market.

Weaknesses:
- The high cost of CGMD devices and associated consumables can be a barrier to adoption, especially in developing regions with limited healthcare budgets.
- Despite improvements, CGMD devices may still face challenges in terms of accuracy and reliability, leading to potential misinterpretation of glucose levels and inappropriate treatment decisions.

Opportunities:
- The growing demand for minimally invasive and non-invasive glucose monitoring solutions presents an opportunity for CGMD manufacturers to develop innovative products that cater to these needs.
- The expanding adoption of CGMD devices in emerging economies, where the prevalence of diabetes is high, offers significant market potential for manufacturers to tap into.

Threats:
- Intense competition in the CGMD market poses a threat to existing players, as new entrants continually introduce innovative products and technologies.
- Regulatory challenges and stringent approval processes can hinder the market growth and delay the commercialization of new CGMD devices.

Key Takeaways:

The Global Continuous Glucose Monitoring Devices Market Demand is expected to witness high growth, exhibiting a CAGR of 9.9% over the forecast period (2023-2030), due to increasing diabetes prevalence and the adoption of advanced CGMD technologies.

The US is the fastest growing and dominating region in the market, driven by the high prevalence of diabetes and favorable reimbursement policies.

Key players operating in the CGMD market include Medtronic, Dexcom, Inc., Abbott, Novo Nordisk A/S, Ypsomed, GlySens Incorporated, and F. Hoffmann-La Roche Ltd., among others.